YES1 and neoplasm: Garmendia et al. demonstrated that the in vivo treatment of NSCLC cell lines with dasatinib significantly decreased the tumor burden in cell lines that overexpressed, but had minimal effect on cell lines where the expression of Yes was lower [33].